Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis

Vaccine

Volumn 22, Issue 15-16, 2004, Pages 1930-1940

  Zadeh Vakili, Azita ^a   Taheri, Tahere ^a   Taslimi, Yasaman ^a   Doustdari, Fatemeh ^a   Salmanian, Ali Hatef ^b   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

Author keywords

Cysteine proteinases Type I and Type II; Hybrid protein vaccination; L. major

Indexed keywords

CYSTEINE PROTEINASE; CYSTEINE PROTEINASE 1; CYSTEINE PROTEINASE 2; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PLASMID DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE;

3' UNTRANSLATED REGION; ACTIVE IMMUNIZATION; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPA GENE; CPB GENE; DRUG TARGETING; FEMALE; FOOT PAD; GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE LOCUS; GENETIC CODE; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; INTERMETHOD COMPARISON; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROVOCATION TEST; TANDEM REPEAT; VACCINE PRODUCTION;

ANIMALS; CYSTEINE ENDOPEPTIDASES; CYTOKINES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MONOCYTES; PLASMIDS; PROTOZOAN VACCINES; TH1 CELLS; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS;

EID: 2342461107     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.014     Document Type: Article

References (33)

1. Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14(2):2001;229
2. Herwaldt B. Leishmaniasis. In: Fauci A, Braunwald E, Isselbacher KJ, editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 1998. p. 1189.
3. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186(7):1997;1137
4. Walker P.S., Scharton-Kersten T., Rowton E.D. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum. Gene. Ther. 9:1998;1899
5. Handman E., Symons F.M., Baldwin T.M., Curtis J.M., Scheerlinck J.P. Protective vaccination with promastigote surface antigen 2 for Leishmania major is mediated by a TH1 type of immune response. Infect. Immunol. 63:1995;4261
6. Webb J.R., Kaufmann D., Campos-Neto A., Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:1996;5034
7. Webb J.R., Compos-Neto A., Ovendale P.J., Martine T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66(7):1998;3279
8. Solioz N., Blum-Tirouvanziam U., Jacquet R., Rafati S., Corradin G., Mauëi J., et al. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine. 18:1999;850
9. Rafati S., Fasel N., Masina S. Leishmania cysteine proteinases: from gene to subunit vaccine. Curr. Genom. 4:2003;109
10. Robertson CD, Coombs GH, North MJ, Mottram JC. Parasite cysteine proteinases. In: Mckerrow JH, James MNG, editors. Cysteine proteinases, vol. 6. ESCOM Science Publisher, 1996. p. 99.
11. Wolfram M., Ilg T., Mottram J.C., Overath P. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells specific for amastigotes cysteine proteinases requires intracellular killing of the parasites. Eur. J. Immunol. 25:1995;1094
12. Coombs GH, Robertson CD, Mottram JC. Cysteine proteinases of leishmaniasis. In: Proteinases of trypanosomes and leishmania: biology and control. Oxford: CBA International, 1997. p. 209.
13. Rafati S., Couty-Jouve S., Alimohamadian M.H., Dowlati Y. Evaluation of cellular immune responses to amastigote soluble Leishmania major antigens in recovered cases of cutaneous leishmaniasis. Med. J. Islamic Repub. Iran. 11:1997;133
14. Rafati S., Salmanian A.H., Hashemi K., Schaff C., Belli S., Fasel N. Identification of Leishmania major cysteine proteinases as target of the immune response in humans. Mol. Biochem. Parasitol. 113:2001;35
15. + T lymphocytes activation. Vaccine. 20:2002;2439
16. Rafati S., Salmanian A.H., Taheri T., Vafa M., Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 19(25-26):2001;3369
17. Li M., Bi H., Dong W., Xu W., Li Q., Li Y. A recombinant multi-epitope, multi-stage malaria vaccine candidate expressed in Escherichia coli. Chin. Med. J. 112(8):1999;691
18. Wunderlich G., Moura I.C., del Protillo H.A. Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis virus surface protein fusion protects mice against lethal plasmodium chabaudi chabaudi PC1 infection. Infect. Immun. 68(10):2000;5839
19. Coler R.N., Skeiky Y.A.W., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein, and Leishmania elongation initiation factor protects against Leishmaniasis. Infect. Immun. 70(8):2002;4215
20. Sakanari J.A., Nadler S.A., Chan V.J., Engel J.C., Leptak C., Bouvier J. Leishmania major: comparison of the cathepsin L- and B-like cysteine proteinase gene with those of other trypanosomatids. Exp. Parasitol. 85:1997;63
21. 4. Nature. 227:1970;680
22. Rey-Ladino J.A., Joshi P.B., Singh B., Gupta R., Reiner N.E. Leishmania major: molecular cloning, sequencing and expression of the heat shock protein 60 gene reveals unique carboxy terminal peptide sequences. Exp. Parasitol. 85:1997;249
23. Ortiz M.L., Calero M., Patron C.F., Castellanos L., Mendez E. Immidazole-SDS-Zn reverse staining of proteins in gels containing or not SDS and microsequence of individual unmodified electroblotted proteins. FEBS. 296(3):1992;300
24. Cazzulo J.J., Martinez J., Parodi A.J.A., Wernstent C., Hellman U. On the post-translational modifications at the C-terminal domain of the major cysteine proteinase from Trypanosoma cruzi. FEMS Microbiol. Lett. 79:1992;411
25. Alexander J., Coombs G.H., Mottram J.C. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161:1998;6794
26. Mottram J.C., Brooks D.R., Coombs G.H. Roles of cysteine proteinases of Leishmania in host-parasite interaction. Curr. Opin. Microbiol. 1:1998;455
27. Pollock K.G.J., McNeil K.S., Mottram J.C., Lyons R.E., Brewer J.M., Scott P., et al. The Leishmania mexicana Cysteine Proteinase CPB2.8, induces potent Th2 responses. J. Immunol. 170:2003;1746
28. Rafati S., Abraham baba A., Bakhshayesh M., Vafa M. Vaccination of BALB/c mice with Leishmania major amastigote-specific Cysteine Proteinase. Clin. Exp. Immunol. 120:2000;134
29. Beyrodt C.P.G., Pinto A.R., Freymüller E., Barbiéri C.L. Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Infect. Immun. 65:1997;2052
30. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Skeiky Y.A.W., et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models. Infect. Immun. 69:2001;4103
31. Spitzer N., Jardim A., Lippert D., Olafson R.W. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine. 17:1999;1298
32. Rafati S., Couty-Jouve S., Alimohamadian M.H., Louis J.A. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis. Clin. Exp. Immunol. 110:1997;203
33. Pascalis H., Lavergne A., Bourreau E., Kariminia A., Pradinaud R., Rafati S., et al. TH1 cell development towards cysteine proteinases A and B in localized cutaneous leishmaniasis due to L. guyanensis. Infect. Immunol. 71:2003;2924